3.87
Qualigen Therapeutics Inc Borsa (QLGN) Ultime notizie
Qualigen Therapeutics (QLGN) Faces Nasdaq Compliance Challenge | - GuruFocus
Qualigen Therapeutics, Inc. Receives Notification of Deficiency - GuruFocus
Qualigen Therapeutics Faces Nasdaq Delisting Threat - TipRanks
Qualigen Therapeutics, Inc. Faces Nasdaq Delisting Due to Late Filing of 2024 Form 10-K - Nasdaq
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K - TradingView
QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN
Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa
Qualigen Therapeutics secures $4.5 million in funding - Investing.com India
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics Inc (QLGN) Quarterly 10-Q Report - Quartzy
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com Canada
Qualigen Therapeutics Appoints Graydon Bensler to Board - TipRanks
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com Canada
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com
Qualigen Therapeutics announces 1-for-50 reverse stock split By Investing.com - Investing.com UK
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Qualigen Therapeutics announces results of annual stockholder meeting - Investing.com
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR.com
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com India
Qualigen Therapeutics appoints new director and audit chair By Investing.com - Investing.com UK
Qualigen Therapeutics, Inc. Announces management changes. - GlobeNewswire
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - GlobeNewswire
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):